Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Despite concrete steps forward, the ENVI vote on clinical trials regulation falls short on transparency
Bracing for another delay – open innovation at the WHO?
EU Policy Opportunities in Biomedical Innovation and the Public Good
Statement on Medicines Patent Pool
Public Event on EU-MERCOSUR in Buenos Aires
Study provides recommendations on European Medicines Agency's communication on medicines
The Diagnosis of Childhood Bipolar Disease has led to Catastrophic Consequences
DG Trade State of Play reveals EU's ambitions for IP protection in FTAs
TRIPS-Plus IP demands from EU could halt South American trade deal
EU Mercosur Trade Negotiations in July
HAI Europe’s participation at the “Ad hoc meeting – Bilateral trade negotiations: State of Play”
Conflicts of interest at the European Medicines Agency (EMA) and the need for a review of staff regulations
Submission to the Consultative Expert Working Group (CEWG) on alternative financing
HAI Europe injects public health perspective into European Research and Innovation Framework
Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN
Conflicts of Interest and the Future of Financing for WHO.
DG Trade public hearing on the “Protection and enforcement of IPR in third countries
EU-Mercosur Trade Negotiations: What Fate for Access to medicines?
Foundations: Conlicts of interests and Democracy issues
European drug regulator challenged over revolving door case involving former Director
Corporate funding linked to EU patient & consumer groups policy